University of Iowa Department of Psychiatry Lifespan Clinical Neuropsychology

APPCN MEMBER SINCE 2018

University of Iowa Department of Psychiatry Lifespan Clinical Neuropsychology
Program director name: Douglas Whiteside, PhD, ABPP
Mailing address: Department of Psychiatry, UIHC, 200 Hawkins Drive, Iowa City, IA 52242
Telephone #: 319-356-1103
Fax #: NA
E-mail address: douglas-whiteside@uiowa.edu 

For a detailed program description click on this link: https://medicine.uiowa.edu/psychiatry/education/fellowship-programs/postdoctoral-residency-lifespan-clinical-neuropsychology

Program will do interviews at INS in 2019: Yes
Policy regarding on-site interviews: Competitive applicants will be contacted and invited to interview with program faculty at INS. Applicants are encouraged to contact previous postdoctoral residents. Previous pediatric neuropsychology experience is not required.

2019 application deadline: December 17, 2018
2019 residency start date: August 1, 2019 (flexible if needed)

Clinical neuropsychology residency openings for 2019: 1
Clinical neuropsychology residency positions: 1
Residency/fellowship positions in psychology: N/A

Clinical neuropsychologists: 4 Full-time, 1 Part-time
With ABCN/ABPP: 3 Full-time; 1 Part-time
(please see webpage for faculty)

Other psychologists: 21
With ABPP: 1

Graduate training of residency applicants:

Preferred: Clinical Psychology, Counseling Psychology
Accepted: Neuropsychology, School Psychology
Not Accepted: Non-APA/CPA accredited programs

Primary emphasis: Lifespan Neuropsychology-Adults and Pediatrics

Emphases of training opportunities:

Strong: neuropsychological assessment, neuropsychological development, neuropsychological consultation, research, resident supervision of psychometrists and practicum students
Moderate: Cognitive Rehabilitation, medico-legal consultation
Weak: Psychotherapy

Availability of patient populations:

Strong: Neuropsychiatric disorders, dementia, traumatic brain injury, metabolic and other chronic health conditions, neurological disorders, oncology, organ transplant, and learning disorders/ADHD.
Moderate: multiple sclerosis, HIV
Weak: Wada testing

updated: 10/10/18